5th Cancer Epigenetics

5th Oncology Partnering & Deal-Making

2nd Cancer Diagnostics

Cancer Immunotherapy

GTCbio offers comprehensive sponsorship packages for all our meetings, including presentation opportunities, exhibit and booth space, as well as the event delegate list. All our packages can be customized to meet your company's budget. For information, please contact us.
GTCbio encourages attendees to showcase their research at the conference by presenting a poster. The top 2-3 submitted posters will also be selected to give short oral presentations as part of the meeting program. Abstracts will be accepted until October 7, 2016; slots fill up quickly so submit yours online ASAP!
Novel Cancer Therapeutics Summit 2016
Venue: Parc 55 Hotel, San Francisco, CA, USA
Date: 7 - 9 November, 2016

Dear Colleague,

We invite you to attend the 2016 Novel Cancer Therapeutics Summit, to be held on November 7-9, 2016 in San Francisco, CA. This summit includes four parallel conferences focused on both the research, and business perspectives in oncology.

This summit will continue to be a premier event for translational researchers, preclinical scientists and managers, and those carrying out early phase clinical trials working to identify and exploit advances in the field of oncology in order to deliver products with a meaningful clinical impact. In addition, industry leaders from big pharma and various biotech/pharmaceutical companies, including business/corporate development executives, licensing executives, global alliance, and venture capitalists, will all be present to explore potential collaborations and learn about relevant issues in oncology.

Focus areas include cancer diagnostics, cancer immunotherapy, cancer epigenetics, as well as partnering and deal-making in oncology. Discussion topics include emerging targets, therapeutic strategies, epigenetic targets and tools/technologies, next generation sequencing in cancer diagnosis, progress in cancer immunotherapy, combination strategies in immuno-oncology, advancements in technology, as well as business development trends, markets, partnership opportunities, and access to capital market.

Both cutting-edge researchers and those who guide its commercial development will be on-hand to share their knowledge and insights as to how therapeutic cancer targets are identified, and how this research translates into meaningful therapeutics that benefit patients living with cancer!

We hope to see you there!

Best regards,

The 2016 Advisory Committee

antibodies logo